Premium
Cannabis ‐ 1988
Author(s) -
Hollister Leo E.
Publication year - 1988
Publication title -
acta psychiatrica scandinavica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.849
H-Index - 146
eISSN - 1600-0447
pISSN - 0001-690X
DOI - 10.1111/j.1600-0447.1988.tb08576.x
Subject(s) - cannabis , effects of cannabis , psychiatry , schizophrenia (object oriented programming) , panic , tetrahydrocannabinol , drug , medicine , psychology , cannabinoid , anxiety , cannabidiol , receptor
In this updating review of research on cannabis particular attention has been paid to the increasing number of studies of the disposition of the components of cannabis in man, as well as possible effects on health. Specific binding sites for cannaboids have not been demostrated. Approximately 80 metabolites of tetradrocannabiol (THC) have been discovered, of which 11‐OH‐THC is the main metabolite, but it contributes little to the overall effect when the drug is smoked or given intravenously. The minimu plasma level of THC associted with the psychotropic effect is 25 ng/ml. Cannabis may produce directly an acute panic reaction, a toxic delirium, and acute paranoid state, or acute mania. Cannabis use may aggrevate schizophrenia, but it is much less certain whether it can lead to sociopathy or even to “amotivational syndrome”. Despite widespred use of cannabis in virtually all parts of the world, no catastrophic effects on health have been noted. Cannabis appears to be relatively safe as compared with current social drugs. It is, however, still too early in the history of the present episode of cannabis use to be sanguine about possible bad effects.